A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Recipients of first or second cadaveric, living unrelated or living related kidney transplant.
Patients on a reduced daily dose (500mg to 1500mg) of MMF with existing but tolerable and controlled gastrointestinal symptoms.
Recipients who are at least 4 weeks post renal transplantation with stable renal function.
You may not be if
Multi organ transplant or previous transplant with organ other than kidney
History of GI disorder prior to transplant
Evidence of GI disorder induced by infection, underlying medical condition, or con med other than MMF
Modification of GI med or MMF dose within one week
Evidence of graft rejection, treatment of acute rejection, unstable renal function within 1 week of (baseline) visit
Clareo Health | A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms
